PreTT
@pre-tt.com
Revolutionising cancer treatment, PreTT pioneers best-in-class Pretargeted radioligand therapies, surpassing traditional methods. Our exclusive pretargeting technology is set to transform radioimmunotherapies with monoclonal antibodies (mAbs), making a tangible impact in the fight against cancer.
PreTT's Company Logos
PreTT's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#023047
Green Vogue
2, 48, 71
200, 95, 14
97, 32, 0, 72
#FFF8F2
Seashell Peach
255, 248, 242
28, 100, 97
0, 3, 5, 0
#000000
Black
0, 0, 0
0, 0, 0
0, 0, 0, 100
About PreTT
PreTT is at the forefront of theranostics, revolutionizing cancer treatment with best-in-class Pretargeted radioligand therapies. Our pioneering pretargeting technology using monoclonal antibodies (mAbs) is poised to redefine radioimmunotherapies, delivering a significant impact in the battle against cancer. Radioligand Therapy (RLT) is a superior and delicate method for treating tumors using radiation, proving effective where chemotherapies fall short and in treating naïve patients.
Our innovative solution leverages mAbs over peptides for their ease of development, production, selectivity, and radionuclide conjugation, addressing the limitations of traditional RLTs. By separating mAb accumulation and excretion from radiotherapy, our pretargeting platform overcomes radiotoxicity challenges, optimizing treatment efficacy. Connect with our skilled team, led by CEO Francesco Sergi-Lindell and Co-Founder & CMO Andreas Kjær, MD, PhD, to learn more about how PreTT is shaping the future of cancer care
